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Aim.Thepresenceofairbubblesandfoaminstomachandduodenumisacommonproblemduringesophagogastroduodenoscopy
(EGD). Methods. Candidates of elective EGD received 40mg chewable tablet of simethicone (n = 90) or placebo (n = 83), with
30mL water, 15–30min before the EGD. Foam/air bubbles during endoscopy were assessed and graded on a 4-point scale, and
patients’satisfactionwiththeendoscopywasscoredfrom0to10.Results.Theamountofgastricbutnotduodenalfoam/airbubbles
was signiﬁcantly lower in the simethicone group compared with the placebo group (P = 0.002). Duration of endoscopy was, on
average, one minute shorter in the simethicone group compared with the placebo group (P<0.001). Patients’ satisfaction with the
procedure was the same in the two groups. Conclusion. Administration of simethicone prior to EGD reduces the amount of gastric
foam and bubbles and provides better visibility for evaluating the mucosa. It also decreases the duration of endoscopy. Further
trials are required to ﬁnd the ﬁnal eﬀect of the drug on diagnosis of pathological lesions.
1.Introduction
Upper gastrointestinal endoscopy (esophagogastroduo-
denoscopy or EGD) is one of the most common diagnostic
and therapeutic methods of upper gastrointestinal diseases
[1]. One limitation of the method is, however, the presence
of air bubbles and foam in stomach and duodenum,
s u c ht h a ti ti sd i ﬃcult or sometimes impossible for a
gastroenterologist to evaluate the mucosa using the images
obtained in the presence of the bubbles. This will lead to
decreased diagnostic accuracy, prolonged endoscopy time,
and decreased patient’s tolerance [2]. Therefore, gastric and
intestinal preparation prior to endoscopy is necessary for the
removal of the bubbles.
An appropriate preparation method should be able to
remove the bubbles, not having side eﬀects, be tolerable for
patients, and be applicable for most patients in diﬀerent
conditions [3]. Currently, except fasting prior to endoscopy,
no standard method has been recommended for prior EGD
preparation. Although some specialists routinely administer
simethicone for endoscopy preparation [4], according to the
searches performed in medical databases, until conducting
the present study, there was no systematic study on sime-
thicone with respect to its eﬀects and side eﬀects, and also
the potential of the drug to be recommended for all patients.
Simethicone is a detergent, which is a chemical mixture
of dimethyl polysiloxane and silica gel. It is physiologically
inactive and nontoxic. It can be taken orally and cannot be
absorbed through gastrointestinal system [5]. By reducing
the adhesion force of air bubbles, simethicone removes the
bubbles. Thus, it is expected that the drug can be used
for removing gastric and duodenal foams and bubbles [5].
Simethicone does not have any known drug interaction,
and no signiﬁcant complication has been reported for it.
Therefore, the drug has been used for treatment of patients
with vague abdominal complaints (because of large amount
of gases), and positive eﬀects have been observed [6].
Moreover, the drug (in solution formulation) has been
used in some studies for intestinal preparation prior to
colonoscopy and capsule endoscopy [7]. However, thus far,
no reliable report for routine use of the drug in preparation
prior to EGD was available. Thus, we have evaluated the2 Diagnostic and Therapeutic Endoscopy
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Figure 1: Comparison of the amount of gastric foam/air bubbles
between the two groups.
eﬀect of simethicone on the reduction of foam and air
bubbles during upper gastrointestinal endoscopy.
2. Methods
This randomized, placebo-controlled, double-blinded (pa-
tientsandphysician),clinicaltrialwascarriedoutonpatients
above 18, who referred to Poursina Hakim Clinic, Isfahan
(IRAN), for elective EGD. Considering the study power as
to be 80% and determining the type I error as 0.05, and
also setting the minimum expected diﬀerence in average of
foam/air bubbles between the two groups as 0.4, according
to the available data [8], and also assuming 10% for missing
probability, the sample size for each group determined to
be 80. The study was approved by the Ethical Committee
of Isfahan University of Medical Sciences, and all patients
signed an informed written consent.
The sampling was carried out subsequently, and the par-
ticipants were assigned to the simethicone or placebo groups
randomly (according to the computer-generated table of
random numbers) [9]. Fifteen to 30 minutes before EGD,
in the presence of the researcher, the patients chewed a
simethicone (40mg) or placebo tablet, and then took 30mL
of water. Shape, box, and the route of administration of the
drug were the same for the two groups. The placebo was
prepared in the Pharmacy School of Isfahan University of
Medical Sciences from corn starch and in the form and color
of simethicone tablet.
Regarding the previous studies [10, 11], we used a 4-
point scale to separately measure the amount of gastric and
duodenal foam/air bubbles; (0) no air bubbles, (1) there
was a small amount of bubbles, without interfering in the
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Figure 2:Comparisonoftheamountofduodenalfoam/airbubbles
between the two groups.
evaluation, (2) there was a considerable amount of air bub-
bles andfoam,such thatit wassomehow diﬃcultto evaluate,
and (3) mucosal evaluation was hardly possible owing to
the presence of foam and air bubbles. The amount of foam
and air bubbles was recorded immediately at the end of
endoscopyprocedurebythegastroenterologist.Theduration
oftheendoscopyprocedurewasalsomeasuredandrecorded.
If there was a stenosis in the upper gastrointestinal tract,
such that gastric or duodenal evaluation was not possible or
the stenosis led to a prolonged procedure, the patient was
excluded from the study. Moreover, after carrying out the
procedure, the participants’ satisfaction with the endoscopy
procedure was scored on a numerical scale, in which 0
showed the least satisfaction level and 10 showed complete
satisfaction. The data was analyzed by SPSS software, v. 16.0,
using Chi-square test and independent sample t-test. In case
of lack of normal distribution for quantitative data, we used
Mann-Whitney test for comparison of the two groups.
3. Results
We included 90 and 83 patients in the simethicone and
placebo groups, respectively. The two groups were similar
in terms of age and sex. Comparison of the amount of
gastric and duodenal foam/air bubbles in the two groups
is demonstrated in Figures 1 and 2. In the two groups,
the amount of gastric and duodenal foam/air bubbles was
limited to grade 2. The amount of gastric foam/air bubbles
was signiﬁcantly lower in the simethicone group, compared
with that of the placebo group (P = 0.002). However, the
two groups were not signiﬁcantly diﬀerent with regard to the
amount of duodenal foam/air bubbles (P = 0.422).Diagnostic and Therapeutic Endoscopy 3
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Figure 3: Comparison of the endoscopy duration between the two
groups.
Comparison of the two groups with respect to the dura-
tion of endoscopy procedure is demonstrated in Figure 3.
The duration of endoscopy procedure was one minute
shorter in the simethicone group (308.0±116.2 versus 376±
108.1 seconds, P<0.001).
Comparison of the two groups with respect to the
patients’ satisfaction with the endoscopy procedure is shown
in Figure 4. The two groups were not signiﬁcantly diﬀerent
in this regard (P = 0.646).
We did not observe any severe medical complication like
allergic reactions in the simethicone group.
4. Discussion
The aim of the study was to determine the eﬀectiveness
of simethicone in the preparation prior to EGD. According
to the results obtained, simethicone decreased the amount
of gastric air bubbles and foam signiﬁcantly but has no
signiﬁcant eﬀect on the amount of duodenal air bubbles and
foam. Another noteworthy ﬁnding was the decrease in the
endoscopy procedure duration by one minute on average
in the simethicone group. However, simethicone did not
aﬀect the patients’ satisfaction with the procedure. Lack of
signiﬁcant eﬀect on duodenal air bubbles and foams can be
due to the small amount of duodenal air bubbles during the
procedure, such that only 2.4% of all patients had grade 2 of
air bubbles, and, therefore, a larger sample size is required to
evaluate the eﬀect of simethicone in this respect. In addition,
if we want the drug reaching duodenum, a larger amount
of water is required to be taken with the drug. Moreover, in
timing the drug administration, we should take into account
the lagging in emptying gastric content into the duodenum.
According to our literature review, there was only one
report available on the eﬀectiveness of simethicone versus
placebo in preparation prior to EGD, and most studies
evaluated the eﬀectiveness of adding simethicone to the
colonoscopy or capsule endoscopy preparation regimens [7].
In the study carried out by Keeratichananont et al., 121
candidates of EGD received simethicone (2mL) or placebo
solution with 60mL of water, 15 to 30 minutes prior to EGD.
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Figure 4: Comparison of the patients’ satisfaction with the proce-
dure between the two groups.
They observed a decrease in the amount of esophageal, gas-
tric, and duodenal air bubbles and foam in the simethicone
group. Moreover, patients and physicians in the simethicone
group were more satisﬁed with the procedure. However, the
drug did not inﬂuence the duration of endoscopy procedure
[12].Therefore,itseemsthatifwewantthesuﬃcientamount
of drug to reach the duodenum, a larger amount of water
should be taken with the drug. According to the review
and meta-analysis carried out by Wu et al. on 13 placebo-
controlled studies on the eﬀectiveness of simethicone in
capsule endoscopy and colonoscopy, simethicone signiﬁ-
cantly decreases the amount of air bubbles and foams in the
endoscopyﬁeldleadingtoanincreasevisibility.Thisprovides
a better chance for more accurate evaluation of the mucosa.
However, the ﬁnal eﬀect of the drug on the diagnosis of
pathological lesions is not investigated yet [7].
In spite of being placebo-controlled, and also random-
ization, and an appropriate sample size, the present study
had some limitations. The amount of air bubbles and foam
was evaluated by a single person (the endoscopist), on a 0–4
scale. It was better to carry out the evaluation on the basis
of image processing and quantitative scales, to completely
remove measurement errors and biases. Furthermore, it is
not known to what extent a decrease in the amount of air
bubbles and foam, and an increase in the quality of mucosal
images will improve diagnosis of pathological lesions during
endoscopy. Further studies are required in this respect.
5. Conclusion
Using simethicone prior to upper gastrointestinal endoscopy
signiﬁcantlyreducestheamountofairbubblesandfoamand
increase the visibility during the procedure. This provides
the possibility of more accurate evaluation of the mucosa
and also decreases the endoscopy duration. We suggest
comparison of eﬀectiveness of diﬀerent doses, timing of4 Diagnostic and Therapeutic Endoscopy
administration, and volume of simultaneous liquid, as well
as the ﬁnal eﬀect of the drug on diagnosis of pathological
lesions in future studies.
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